96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

(AMACR, FASN, GOLM1, GSP-pi, ERG) that aid in the differential diagnosis
are presented and discussed here.
The clinical decision of urologists or radiooncologists, whom and how
to treat these men, still rests predominantly on histological parameters.
This urges us to increase standardization of the way we handle and diagnose
our specimens. Processing and diagnosing of prostatectomy specimens
has been the topic of the 2009 consensus conference of the International
Society of Urologic Pathology (ISUP) and the most important
recommendations of this conference will be discussed in comparison to
the current S3-guidelines.
As Gleason Score is one of the strongest prognostic parameters in prostate
cancer, standardization is particularly important. The long overdue
update on Gleason scoring by the ISUP 2005 recommendations has generally
increased awareness, but has also led to some confusion among
pathologists and clinicians and has possibly even induced a systematic
over-grading of biopsies. A recent study conducted by the European Network
of Urinary Pathologists focussed on particularly challenging cases
to discriminate problematic areas in the differentiation of Gleason patterns
3 and 4 in order to establish helpful diagnostic guidelines.
Despite the clinical need to identify insignificant and lethal prostate cancer
at the biopsy stage, this estimation is still left exclusively to conventional
clinical and histological parameters and no molecular biomarker has
entered clinical practice yet. A critical overview of recent developments
of prognostic biomarkers in prostate cancer is given.
Finally, a brief outline of the PREFERE study, a prospective therapy study
beginning in late 2012 in Germany, that aims to compare the outcomes
of 7600 patients over a period of nearly 20 years, will be presented.
Gastric Cancer – English
VO-024
Hereditary gastric cancer
F . Carneiro1 1Institute of Molecular Pathology and Immunology of the University of
Porto (IPATIMUP) and Medical Faculty of Porto/Centro Hospitalar S . João,
Porto, Portugal, Porto, Portugal
Familial aggregation of gastric cancer (GC), both of the diffuse and of
the intestinal type, occurs in a variable proportion of cases, pointing to
genetic predisposition in these settings.
In 1998, Guilford et al identified the first inherited gastric cancer syndrome,
designated as Hereditary Diffuse Gastric Cancer (HDGC), caused
by germline alterations at the CDH1 (E-cadherin) gene. In 1999, the
International Gastric Cancer Linkage Consortium (IGCLC) defined the
criteria for the different types of familial gastric cancer syndromes: 1)
two GC cases in a family, one confirmed DGC 80% at the age of 80
in both genders, and lobular breast cancer is 60% in women by age 80.
About one third of families fulfilling the criteria for HDGC carry germline
alterations of the CDH1 gene. To date, about 100 different germline
CDH1 alterations have been identified in HDGC families, mainly point
mutations and large deletions. In 2010, the IGCLC updated the recommendations
for CDH1 testing, including: 1) histological confirmation of
DGC only required for one family member; 2) DGC